Top 10 Urology Times videos from the first half of 2025

The first half of 2025 generated plenty of headlines in the urology space, ranging from conferences such as the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, American Urological Association 2025 Annual Meeting, and ASCO Annual Meeting. Besides conferences, other key headlines involved the FDA’s approval of perioperative durvalumab (Imfinzi) with neoadjuvant chemotherapy for adult patients with

Top 10 Urology Times videos from the first half of 2025

muscle-invasive bladder cancer along with former President Joe Biden’s diagnosis of grade group 5 de novo metastatic hormone-sensitive prostate cancer. In the below round-up, we spoke to experts on these and other notable topics in urology. To keep up on all of our video content, bookmark this link

Matthew Cooperberg, MD, reacts to 2025 ACS prostate cancer data

In this video, Matthew R. Cooperberg, MD, MPH, highlights key prostate cancer data from the American Cancer Society’s Cancer Statistics, 2025 report and considers the causes of the rise in incidence and mortality. Cooperberg is a professor of urology and epidemiology & biostatistics at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center. Watch video here

ASCO GU recap: Insights on 5 key trials

In this video, Urology Times highlights 5 interviews on key trial data presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, California.

Specifically, we showcase:

Fred Saad, MD, FRCS: “Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial”

Nima Sharifi, MD: “HSD3B1 and overall survival (OS) in high-risk non-metastatic (M0) and metastatic (M1) prostate cancer starting androgen deprivation therapy (ADT) in the enzalutamide (ENZ) and abiraterone acetate plus prednisolone (AAP) STAMPEDE phase 3 trial”

Pooja Ghatalia, MD: “A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2)”

Gopa Iyer, MD: “EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC)”

Laurence Albiges, MD, PhD: “Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313”

Watch the video here

Alicia Morgans, MD, MPH, on physician awareness of PSA doubling time in prostate cancer

In this video, Alicia Morgans, MD, MPH, gives an overview of the study “Impact of physicians’ awareness of prostate-specific antigen doubling time (PSADT) on treatment (Tx) decisions in high-risk (HR) biochemically recurrent (BCR) prostate cancer (PC),” which she presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, California. Morgans is a genitourinary medical oncologist and the director of the Survivorship Program at Dana-Farber Cancer Institute in Boston, Massachusetts. Watch the video here

Helen L. Bernie, DO, MPH, on the FDA’s labeling changes for testosterone products

The FDA’s recent announcement of class-wide labeling changes for testosterone products was met with excitement by urologist Helen L. Bernie, DO, MPH. In a video interview with Urology Times, she said, “I'm so excited about them finally removing this boxed warning. I think that's been so important, and I think it's something that many of us who prescribe testosterone therapy often have known for a long time, so it's just nice to finally see this down in paper,” said Bernie, director of sexual and reproductive medicine at Indiana University and an assistant professor of urology at Indiana University School of Medicine in Indianapolis, Indiana. Watch the video here

Chad Ellimoottil, MD, highlights recent telehealth extension

In March 2025, Congress passed the Full-Year Continuing Appropriations and Extensions Act, 2025 (Continuing Resolution) to fund the government through the end of September, which marks the end of the fiscal year. That bill included language to extend telehealth flexibilities through the same time period. Without congressional action, these provisions were set to expire on March 31, 2025. In this video, Chad Ellimoottil, MD, MS, highlights this decision and what it means for urologists, as well as where we’re headed next in terms of continued telehealth coverage. Ellimoottil is the medical director for telehealth and an associate professor of urology at the University of Michigan in Ann Arbor. Watch the video here

Suzanne B. Merrill, MD, FACS, on EAP program for recombinant BCG

Earlier this year, an expanded access program (EAP) to provide recombinant BCG (rBCG) in the US was authorized by the FDA.¹ For the EAP, ImmunityBio has partnered with the Serum Institute of India, which develops rBCG, to provide an alternative source across the US. In an interview with Urology Times, Suzanne B. Merrill, MD, FACS, provided an overview of the EAP. Merrill is a urologic oncologist with Colorado Urology in Lone Tree. Watch the video here

Matthew Galsky, MD, reacts to NIAGARA results, durvalumab approval for MIBC

The FDA recently approved perioperative durvalumab (Imfinzi) with neoadjuvant chemotherapy for adult patients with muscle-invasive bladder cancer (MIBC). The approval was supported by data from the phase 3 NIAGARA trial (NCT03732677), which showed that perioperative durvalumab with neoadjuvant chemotherapy significantly extended event-free survival and overall survival vs neoadjuvant chemotherapy alone. In a recent interview with Urology Times, Matthew D. Galsky, MD, offered his thoughts on the significance of findings from NIAGARA and how the approval of perioperative durvalumab with gemcitabine/cisplatin will impact the multidisciplinary care of patients with MIBC. Galsky is the director of GU medical oncology at the Icahn School of Medicine at Mount Sinai and the associate director for translational research at the Tisch Cancer Institute in New York, New York. Watch the video here

Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025

The 40th Annual European Association of Urology Congress in Madrid, Spain, featured an extensive scientific program. In a recent video for Urology Times, Betty Wang, MD, provided insight on 3 presentations that she believes “may be game changing” in urology. Wang is a Society of Urologic Oncology fellow at Cleveland Clinic in Cleveland, Ohio. Watch the video here

5 key trial insights from AUA 2025

Urology Times was on-site at the American Urological Association 2025 Annual Meeting in Las Vegas, Nevada conducting interviews with experts on key data presented at the meeting. In this video, we feature 5 interviews with presenting authors of top study readouts.

Specifically, we showcase:

Neal D. Shore, MD, FACS: “Sasanlimab in combination with Bacillus Calmette-Guérin improves event-free survival versus Bacillus Calmette Guérin as standard of care in high-risk non-muscle invasive bladder cancer: Phase 3 CREST study results”

Joseph M. Jacob, MD, MCR: “TAR-200 monotherapy in patients with Bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer carcinoma in situ: 1-year durability and patient-reported outcomes from SunRISe-1”

Margaret A. Knoedler, MD: “Multicenter randomized trial comparing pulse-modulated holmium:YAG laser versus thulium fiber laser for dusting renal stones”

Félix Guerrero-Ramos, MD, PhD, FEBU: “TAR-200 monotherapy in patients with Bacillus Calmette-Guérin–unresponsive papillary disease–only high-risk non–muscle-invasive bladder cancer: First results from cohort 4 of SunRISe-1”

John L. Gore, MD, MS, FACS: “Radical cystectomy versus bladder-sparing therapy for recurrent high-grade non-muscle invasive bladder cancer: Results from the comparison of intravesical therapy and surgery as treatment options (CISTO) study” Watch the video here

Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines

Former President Joe Biden’s diagnosis of grade group 5 de novo metastatic hormone-sensitive prostate cancer has sparked many discussions regarding screening, diagnosis, and treatment of the disease. In a recent Special Report series from Urology Times, Michael S. Cookson, MD, MMHC, FACS, and Kelly L. Stratton, MD, FACS, address several of the key points raised by Biden’s diagnosis. Watch the video here

REFERENCE

1. FDA authorizes ImmunityBio to provide recombinant BCG (rBCG) to urologists to address TICE BCG shortage. News release. ImmunityBio. February 19, 2025. Accessed February 19, 2025. https://ir.immunitybio.com/news-releases/news-release-details/fda-authorizes-immunitybio-provide-recombinant-bcg-rbcg